Abhinav Deol
Position Title
Professor - Clinical
Hematology-Oncology
Office Location
Karmanos Cancer Institute4100 John R.
Hudson-Webber Cancer Research Center
Mail Code: HW04HO
Detroit, MI 48201
Office Phone
(313) 576-8093Office Fax
(313) 576-8766Education Training
Education
(1999) MBBS, Government Medical College, Amritsar, Punjab, India
Postgraduate Training
(2007-2010) Hematology Oncology Fellow, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine. Detroit, MI
(2004-2007) Resident, Department of Internal Medicine, Wayne State University School of Medicine/Detroit Medical Center. Detroit, MI
Professional Experience
Faculty Appointments
(2021 - Present) Professor - Clinical, Department of Oncology, Division of Hematology-Oncology, Wayne State University School of Medicine, Detroit, MI
(2016 - 2021) Associate Professor - Clinical, Department of Oncology, Division of Hematology-Oncology, Wayne State University School of Medicine, Detroit, MI
(2010 - 2016) Assistant Professor of Oncology, Division of Hematology & Oncology, Department of Oncology, Wayne State University School of Medicine, Detroit, MI
Hospital or Other Professional Appointments
(2020 - Present) President Elect, Medical Executive Committee, Karmanos Cancer Institute.
(2018 - Program Director, Hematology-Oncology Fellowship Program, Detroit Medical Center/Wayne State University
(2016 - Present) Member, Infection Control Committee, Karmanos Cancer Center
(2012 - Present) Member, Medical Executive Committee, Karmanos Cancer Institute
(2011) Co-Physician Leader, Electronic Medical Records Project, Karmanos Cancer Center
(2011 - Present) Member, Credentialing Committee, Karmanos Cancer Center
(2010 - Present) Clinical Member, Developmental Therapeutics Program, Karmanos Cancer Center
(2010 - Present) Physician, Oncology Department, Karmanos Cancer Center. Detroit, MI
(CPOE) Committee, Karmanos Cancer Center. Detroit, MI
(2011 - 2012) Member, Electronic Medical Records (EMR) Steering Committee, Karmanos Cancer Center, Detroit, MI
(2003) Instructor, Department of Physiology, Government Medical College. Chandigarh, India
(2002) Medical Officer, Arora Neuro Center. Ludhiana, India
(2001) Junior Resident, Department of Surgery, Government Medical College, Chandigarh, India
(2000) Medical Officer, Detoxification and Rehabilitation Center, Guru Nanak Mission Charitable Trust, Ludhiana, India
Major Professional Societies
American Society of Clinical Oncology
American Society of Hematology
American Society of Blood and Marrow Transplantation
Board Certification
American Board of Internal Medicine
American Board of Internal Medicine, Subspecialty Certification in Medical Oncology
American Board of Internal Medicine, Subspecialty in Hematology
Honors and Awards
(2016) Hematology-Oncology Fellowship Program Teaching Award, Wayne State University, Karmanos Cancer Institute, Detroit, MI
(2015) School of Medicine College Teaching Award, Department of Oncology, Wayne State University, Detroit, MI
(2015) Hematology-Oncology Fellowship Program Teaching Award, Wayne State University, Karmanos Cancer Institute, Detroit, MI
(2011) American Society of Blood and Marrow Transplant, Clinical Research Training Course, Santa Fe, NM
(2009) American Society of Hematology Travel Grant, ASH Annual Meeting
(2006) Award for Excellence in Geriatrics. Detroit Receiving Hospital. Detroit, MI
(2005-2006) Resident of the Year Award. Harper University Hospital. Detroit, MI
(2004) Honorable Mention. First Annual AMA-RFS Meeting. Atlanta, GA
(2004) Intern of the Month, Detroit Receiving Hospital. Detroit, MI
Courses taught
6400 Pathophysiology – Hematology Section
Medical Resident Instruction
Research Interests
Hematopoietic Stem Cell Transplant
Acute/ Chronic Leukemia, Lymphomas
Publications
Vaishampayan UN, Thakur A, Chen W, Deol A, Patel M, Dobson K, Dickow B, Schalk D, Schienschang A, Whitaker S, Polend A, Fontana JA, Heath EI, Lum LG. Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 10/18/2022. PubMed PMID: 36255393.
Al-Share B, Assad H, Abrams J, Deol A, Alavi A, Modi D, Kin A, Ratanatharathorn V, Uberti J, Ayash L. Role of HighDose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review.. Journal of oncology. 09/30/2022;2022:3472324. PubMed PMID: 36213836.
Slade M, Martin TG, Nathwani N, Fiala MA, Rettig MP, Gao F, Deol A, Buadi FK, Kaufman JL, Hofmeister CC, Gregory TK, Berdeja J, Chari A, Rosko A, Vij R. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma.. Leukemia. 09/16/2022. PubMed PMID: 36114265.
Rotz SJ, Yi JC, Hamilton BK, Wei W, Preussler JM, Cerny J, Deol A, Jim H, Khera N, Hahn T, Hashmi SK, Holtan S, Jaglowski SM, Loren AW, McGuirk J, Reynolds J, Saber W, Savani BN, Stiff P, Uberti J, Wingard JR, Wood WA, Baker KS, Majhail NS, Syrjala KL. Health Related Quality of Life in Young Adults Survivors of Hematopoietic Cell Transplantation.. Transplantation and cellular therapy. 07/21/2022. PubMed PMID: 35872304.
Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Ciltacabtagene Autoleucel, an Anti-Bcell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 06/04/2022:JCO2200842. PubMed PMID: 35658469.
Hoda D, Richards R, Faber EA, Deol A, Hunter BD, Weber E, DiFilippo H, Henderson-Clark T, Meaux L, Crivera C, Riccobono C, Garrett A, Jackson CC, Fowler J, Theocharous P, Stewart R, Lorden AL, Porter DL, Berger A. Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.. Future oncology (London, England). 06/01/2022;18(19):2415-2431. PubMed PMID: 35583358.
Jacobs MT, Jain MD, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan PM, Oluwole OO, McGuirk J, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Ghobadi A, Locke FL. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.. Clinical lymphoma, myeloma & leukemia. 05/23/2022. PubMed PMID: 35780055.
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.. Transplantation and cellular therapy. 04/01/2022;28(4):187.e1-187.e10. PubMed PMID: 35081472.
Singh V, Kim S, Deol A, Uberti JP, Modi D. Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.. Leukemia & lymphoma. 04/01/2022;63(4):855-864. PubMed PMID: 34866528.
Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.. Leukemia & lymphoma. 04/01/2022;63(4):813-820. PubMed PMID: 34781825.
Modi D, Kondrat K, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Post-transplant Cyclophosphamide Versus Thymoglobulin in HLA-Mismatched Unrelated Donor Transplant for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.. Transplantation and cellular therapy. 09/01/2021;27(9):760-767. PubMed PMID: 34174469.
Albanyan O, Alkassis S, Kim S, Kin A, Alavi A, Ayash L, Ratanatharathorn V, Modi D, Uberti JP, Deol A. Impact of pretransplant induction therapy on outcomes of patients who undergo autologous stem cell transplantation for mantle cell lymphoma in first complete remission.. Hematology/oncology and stem cell therapy. 08/17/2021. PubMed PMID: 34425096.
Modi D, Chi J, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation.. Transplantation and cellular therapy. 08/01/2021;27(8):665.e1-665.e7. PubMed PMID: 33991722.
Modi D, Albanyan O, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation.. Leukemia & lymphoma. 08/01/2021;62(8):1982-1989. PubMed PMID: 33627028.
Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Kim JJ, Bashir Z, McLeroy J, Zheng Y, Rossi JM, Johnson L, Goyal L, van Meerten T. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.. British journal of haematology. 08/01/2021;194(4):690-700. PubMed PMID: 34296427.
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.. Lancet (London, England). 07/24/2021;398(10297):314-324. PubMed PMID: 34175021.
Lum LG, Al-Kadhimi Z, Deol A, Kondadasula V, Schalk D, Tomashewski E, Steele P, Fields K, Giroux M, Liu Q, Flaherty L, Simon M, Thakur A. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.. Journal for immunotherapy of cancer. 06/01/2021;9(6). PubMed PMID: 34117114.
Modi D, Singh V, Kim S, Ayash L, Deol A, Ratanatharathorn V, Uberti JP. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.. Annals of hematology. 02/16/2021. PubMed PMID: 33594448. 1
Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, Rowley SD, Kim DDH, Hernandez D, Rajkhowa T, Haines K, Bonifacio G, Rine P, Purkayastha D, Fernandez HF. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.. Bone marrow transplantation. 12/07/2020. PubMed PMID: 33288862.
Modi D, Kim S, Surapaneni M, Ayash L, Ratanatharathorn V, Uberti JP, Deol A. Absolute lymphocyte count on the first day of thymoglobulin predicts relapse-free survival in matched unrelated peripheral blood stem cell transplantation.. Leukemia & lymphoma. 12/01/2020;61(13):3137-3145. PubMed PMID: 32779495.
Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose J, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill B, Miklos DB. Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.. Blood. 11/06/2020. PubMed PMID: 33156925.
Modi D, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Comparison of myeloablative and reduced intensity conditioning regimens in haploidentical peripheral blood stem cell transplantation.. Bone marrow transplantation. 10/16/2020. PubMed PMID: 33060839.
Singh V, Jang H, Kim S, Ayash L, Alavi A, Ratanatharathorn V, Uberti JP, Deol A. G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD.. Leukemia & lymphoma. 10/12/2020:1-8. PubMed PMID: 33043743.
Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 09/20/2020;38(27):3119-3128. PubMed PMID: 32401634.
Abdallah N, Kim S, Ayash L, Klimecki S, Ventimiglia M, Alavi A, Ratanatharathorn V, Uberti J, Deol A. Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?. Bone marrow transplantation. 08/01/2020;55(8):1655-1657. PubMed PMID: 31740765.
Modi D, Chi J, Kim S, Ayash L, Alavi A, Kin A, Ratanatharathorn V, Uberti JP, Deol A. Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.. Leukemia & lymphoma. 08/01/2020;61(8):1877-1884. PubMed PMID: 32270725.
Lum LG, Thakur A, Choi M, Deol A, Kondadasula V, Schalk D, Fields K, Dufrense M, Philip P, Dyson G, Aon HD, Shields AF. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.. Oncoimmunology. 06/10/2020;9(1):1773201. PubMed PMID: 32939319.
Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.. Blood. 06/04/2020;135(23):2106-2109. PubMed PMID: 32181801.
Modi D, Kim S, Surapaneni M, Ayash L, Alavi A, Ratanatharathorn V, Deol A, Uberti JP. R-BEAM versus ReducedIntensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 04/01/2020;26(4):683-690. PubMed PMID: 31682979.
Deol A, Uberti J. Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma.. American journal of hematology. 03/01/2020;95(3):333-334. PubMed PMID: 31429117.
Shah H, Kim S, Singh P, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Deol A. Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts.. American journal of hematology. 02/01/2020;95(2):198-204. PubMed PMID: 31691333.
Harsh Shah, Seong Ho Kim, P Singh, Asif Alavi, Voravit Ratanatharathorn, Lois J Ayash, Joseph P Uberti, Abhinav Deol. Clinical Outcomes of Multiple Myeloma Patients Who Undergo Autologous Hematopoietic Stem Cell Transpalnt with GCSF or G-CSF and Plerixafor Mobilized Grafts. American Journal of Hematology. 02/2020;95(2):198-204. doi: 10.1002/ajh.25672.